Wed, November 18, 2009
Tue, November 17, 2009
[ Tue, Nov 17th 2009 ]: Market Wire
Zaio engages Nasoft USA
Mon, November 16, 2009
[ Mon, Nov 16th 2009 ]: Market Wire
Goldcorp to Acquire Canplats
Sun, November 15, 2009
Fri, November 13, 2009
Thu, November 12, 2009
Wed, November 11, 2009
[ Wed, Nov 11th 2009 ]: Market Wire
Reko Refiles Documents
Tue, November 10, 2009
Mon, November 9, 2009
Sun, November 8, 2009
Sat, November 7, 2009
Fri, November 6, 2009

Bradmer announces 2009 third quarter financial results

  Copy link into your clipboard //business-finance.news-articles.net/content/200 .. ounces-2009-third-quarter-financial-results.html
  Print publication without navigation Published in Business and Finance on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

 Bradmer Pharmaceuticals Inc. Balance Sheets (Expressed in United States Dollars) ------------------------------------------------------------------------- September 30 December 31 2009 2008 ------------------------------------------------------------------------- (audited) Assets Current Cash and cash equivalents $ 1,443,036 $ 8,245,455 Amounts receivable 5,648 12,520 Prepaid expenses 31,267 27,158 ------------------------------------------------------------------------- 1,479,951 8,285,133 Patent rights - 711,054 ------------------------------------------------------------------------- $ 1,479,951 $ 8,996,187 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Liabilities Current Accounts payable and accrued liabilities $ 254,312 $ 1,594,578 ------------------------------------------------------------------------- Shareholders' Equity Capital stock 955,520 31,026,728 Warrants 783,988 881,488 Contributed surplus 1,210,796 1,158,886 Deficit (1,724,665) (25,665,493) ------------------------------------------------------------------------- 1,225,639 7,401,609 ------------------------------------------------------------------------- $ 1,479,951 $ 8,996,187 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Bradmer Pharmaceuticals Inc. Statements of Operations and Deficit (Expressed in United States Dollars) (unaudited) ------------------------------------------------------------------------- Nine Months Ended Three Months Ended September 30 September 30 2009 2008 2009 2008 ------------------------------------------------------------------------- Expenses Research expenses $ 2,289,383 $ 6,741,195 $ 43,513 $ 1,908,153 General and adminis- trative 1,685,939 2,628,846 187,436 768,454 Amortization of patents 47,397 45,549 15,202 15,747 Foreign exchange loss 4,352 14,432 3,755 3,032 Write-down of patent rights 672,865 - 472,865 - ------------------------------------------------------------------------- 4,699,936 9,430,022 722,771 2,695,386 Interest income 23,916 228,099 1,039 68,725 ------------------------------------------------------------------------- Net loss (4,676,020) (9,201,923) (721,732) (2,626,661) Deficit at beginning of period (25,665,493) (14,136,436) (29,619,781) (20,711,698) Application of stated capital against deficit 28,616,848 - 28,616,848 - ------------------------------------------------------------------------- Deficit at end of period $ (1,724,665) $(23,338,359) $ (1,724,665) $(23,338,359) ------------------------------------------------------------------------- Basic and diluted loss per share $ (0.36) $ (0.68) $ (0.06) $ (0.19) ------------------------------------------------------------------------- ------------------------------------------------------------------------- Weighted average number of shares 12,886,915 13,488,215 11,832,537 13,488,215 ------------------------------------------------------------------------- Bradmer Pharmaceuticals Inc. Statements of Cash Flows (Expressed in United States Dollars) (unaudited) ------------------------------------------------------------------------- Nine Months Ended Three Months Ended September 30 September 30 2009 2008 2009 2008 ------------------------------------------------------------------------- Cash flows from operating activities Net loss for the period $ (4,676,020) $ (9,201,923) $ (721,732) $ (2,626,661) Add items not affecting cash Amortization of patents 47,397 45,549 15,202 15,747 Stock based compensation (recovery) (45,590) 394,567 (138,192) 113,253 Accrued interest on short-term investment - - - 31,944 Write-down of patent rights 672,865 - 472,865 - ------------------------------------------------------------------------- (4,001,348) (8,761,807) (371,857) (2,465,717) Changes in non-cash working capital items Amounts receivable 6,872 139,163 (1,628) 13,510 Prepaid expenses (4,109) (22,339) 14,048 5,297 Accounts payable and accrued liabilities (1,340,266) 490,639 (200,988) 439,078 ------------------------------------------------------------------------- (5,338,851) (8,154,344) (560,425) (2,007,832) ------------------------------------------------------------------------- Cash flows from investing activities Investment in patent rights (9,208) (68,086) (4,000) (33,471) Purchase of short-term investment - (10,000,000) - - Redemption of short-term investment - 10,000,000 - 10,000,000 ------------------------------------------------------------------------- (9,208) (68,086) (4,000) 9,966,529 ------------------------------------------------------------------------- Cash flows from financing activities Repurchase of common shares (1,454,360) - (1,454,360) - ------------------------------------------------------------------------- Increase (Decrease) in cash and cash equiva- lents during the period (6,802,419) (8,222,430) (2,018,785) 7,958,697 Cash and cash equivalents at beginning of period 8,245,455 19,469,337 3,461,821 3,288,210 ------------------------------------------------------------------------- Cash and cash equivalents at end of period $ 1,443,036 $ 11,246,907 $ 1,443,036 $ 11,246,907 ------------------------------------------------------------------------- -------------------------------------------------------------------------